Abevmy News Today

Abevmy, co-developed by Biocon Biologics and Viatris, is a biosimilar to Roche’s Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications.

Biocon Biologics, Viatris get CHMP nod for Abevmy March 01, 2021 Kiran Mazumdar-Shaw, Chairperson, Biocon× Drug is a biologic therapy for metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer Biocon Biologics Ltd (a subsidiary of Biocon Ltd ) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation of its biosimilar Bev...

Biocon Biologics and Viatris Inc receive CHMP nod for Abevmy®, a Biosimilar to Avastin® Bevacizumab Bangaluru, Mar 1 (UNI) Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced on Monday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of their biosimilar Bevacizumab, co-developed with Viatris, to be marketed as Abevmy®(injection bevacizumab 100mg and 400mg). A stateme...